AIM Breakfasts

AIM BREAKFAST – 14th February 2017

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 972

Total number of AIM Companies trading: 952*
* As at 13 February 2017

Dish of the Day:

No AIM Joiners Today

Off the Menu:

No AIM Leavers Today

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): 85*

Total number of ISDX Growth Market Companies trading: 82*
* As at 13 February 2017

Dish of the Day:

No NEX Growth Market Joiners Today

Off the Menu:

No NEX Growth Market Leavers Today

What’s Cooking in the IPO Kitchen?

Xafinity –Publication of prospectus. The pensions actuarial, consulting and administration business  has conditionally raised £179.6m. At 139p. Due to join main market 16 Feb.

Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime.  Issue closing 23 Feb.

Arix Bioscience — Intention to float on the main market from the  global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management

Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.

 

Breakfast Buffet

Electric Word (ELE.L) 3.5p £14.3m

FYNov16 results from the specialist information business providing information and consultancy to executives working in the business of Sport. Strategic refocus completed with disposals of the Group’s stake in iGaming Business, Optimus Education and Speechmark Publishing, following 2015 disposals of Radcliffe Solutions and Radcliffe Publishing. Group profit for the year of £9.2m (2015: £2.3m loss) including £10.7m profit (2015: £1.8m loss) from discontinued operations. £13.9m net cash inflow from disposals, leaves the Group with £13.0m net cash at 30 November 2016 (2015: £0.4m). Continuing revenues increased by 16% to £2.8m driven by subscriptions growth of 18% (2015: £2.4m). Adjusted EBITA* from trading activities (before central costs) increased by 124% to £0.34m (2015: £0.15m).

 

Sylvania Platinum (SLP.L) 11.5p £33.34m

HYDec16 results. Group EBITDA has increased to $9.22 million from $3.61 million in H1 FY2016 (H2 FY2016: $7.19 million); Net profit increased to $4.52 million from $0.28 million in H1 FY2016 (H2 FY2016: $3.21 million); Revenue has increased 32% to $24.55 million from $18.53 million in H1 FY2016 (H2 FY2016: $20.66 million); Expects to exceed the previously stated guidance of 60,000 ounces by approximately 3,000 to 5,000 ounces. 8.7x FY Jun 2017e PE

 

BlueRock Diamonds (BRD.L) 4.75p £2.65m

Update on operations at Kareevlei, its licence area in the Northern Cape of South Africa containing five known kimberlite pipes.  The first blast of the current series was completed successfully on 9 February 2017, liberating approximately 15,000 tonnes of kimberlite.  Material from this blast is now being processed through the processing plant.   The new primary crushing and screening circuit is expected be commissioned later this week when volumes will start to gradually ramp up. “We are pleased with the results of the blast that was undertaken by our new contractor, African Mining and Crushing, and it is encouraging that we are finally processing run of mine material for the first time since June 2016.  I look forward to updating the market on our progress in the near future.”

 

Alba Minerals (ALBA.L) 0.36p £6.63m

Limerick Base Metals Project, Ireland—The Company has now received the full laboratory assay results from select soil samples taken during the recent programme.  Assay results confirm four main areas of anomalism. Most pronounced anomalism for copper-silver-arsenic (Cu-Ag-As) similar to that found at former Gortdrum copper-silver (Cu-Ag) mine 25 km due east. Gortdrum was mined for copper-silver-mercury (Cu-Ag-Hg) between 1967 and 1975, producing 3.8 million tonnes containing 1.19% Cu and 25.1 g/t Ag.  This target in particular will be the focus of the next stage of work.

 

RWS Holdings (RWS.L) 338.25p £729.8m

The provider of intellectual property support services, commercial translations and linguistic validation,  announced the proposed acquisition of 100% of LUZ, Inc., a market leading Life Sciences language services provider based in San Francisco, for a cash consideration of US$82.5m. The Group also announced a placing at 330p to raise gross proceeds of £40.0m  to part-fund the Acquisition. The Acquisition and Placing are expected to be immediately earnings enhancing. FYSep17E £139.6m rev and £34.8m PBT. Div 6.4p.

 

Altitude Group (ALT.L) 89.5p £41.5m

The provider of innovative technology solutions for small to medium sized businesses, announced that results for the year ended 31 December 2016 are expected, subject to audit, to be marginally ahead of market expectations due to tight control of costs. Annualised cost reductions of approximately £1.8 million resulting from the significant restructuring of the Group were realised during the year. FYDec16e £4.5m rev and £0.5m PBT rising to £6.8m £2m for FYDec17e.

 

Allergy Therapeutics (AGY.L) 24.5p £145.39m

The fully integrated specialty pharmaceutical Company specialising in allergy vaccines, announced that the Phase I clinical study investigating the safety and tolerability of Acarovac MPL (monophosphoryl lipid A) has received Clinical Trial Application (CTA) approval in Spain. This is for a modified house dust mite allergy vaccine. ‘We aim to improve both safety and efficacy for the thousands of patients who suffer year-round due to house dust mite allergy.’ FYJun17E £61.5m rev and £3.72m PBT loss.

 

Keras Resources (KRS.L) 0.47p £8.17m

Initial Inferred Mineral Resource at the Copenhagen Deposit, which along with the Company’s flagship Klondyke Gold Project, comprises the Warrawoona Gold Project  in the East Pilbara Gold Belt of the Pilbara Goldfield of Western Australia.  Inferred Mineral Resource of 180,000t @ 6.1 g/t Au (‘gold’) for 36,000oz at the Copenhagen deposit.      Total Inferred Mineral Resource Inventory for Warrawoona now stands at 5.8Mt @ 2.2g/t Au for 410,000oz. Significant further upside – deposit remains open both down dip and along  strike. Copenhagen will be a priority drill target post the proposed ASX listing.

 

Xeros Technology Group(XSG.L) 249.75p £214.84m

The developer and provider of patented polymer based systems with multiple commercial applications, has launched a US-approved polymer cleaning solution for firefighters’ personal protection equipment (‘PPE’). The PPE solution will be delivered as part of Xeros’ existing Sbeadycare®service and is now available to the more than 58,000 fire stations in the USA. The system will also be used to clean high performance workwear and technical protective equipment in other markets including, amongst others, petroleum, mining, construction and military agencies.

 

SRT Marine Systems (SRT.L) 58.75p £51.04m

SRT has received and shipped an order for 1,500 basic I100 Identifier VMS AIS Transceivers with SAT-Trak technology which will be deployed in Africa for the tracking and identification of small fishing vessels as part of a government supported program. The I100 Identifier AIS Transceivers will be installed on small fishing boats and powered from their integrated re-chargeable batteries which can permit continuous operation for up to 240 hours between charges.  “We continue to negotiate a number of other contracts and will update the market at the appropriate time.”  FYMar17e rev of £12m and £0.7m PBT.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.